Ascelia Pharma gets US patent for second generation Mangoral
HELSINKI: Ascelia Pharma AB announced that the US Patent Office (USPTO) has issued a new patent covering a second-generation formulation of lead drug candidate Mangoral, currently in the pivotal Phase 3 study SPARKLE. The new patent further improves the unique…